Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of MEDI3506 in Adults with Moderate-to-severe Atopic Dermatitis
2019-003304-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MEDI3506 arm with Placebo arm (2 arms). Started Dec 2019; status: completed.
02
Drugs
tozorakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2019-003304-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003304-12.